M. Lazzarino et al., DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma, BONE MAR TR, 28(9), 2001, pp. 835-839
Citations number
22
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) has proved
to be an effective salvage therapy for refractory-relapsed MM patients. Li
ttle is known, however, about its potential as mobilizing therapy. The aim
of this study was to evaluate the efficacy of DCEP in mobilizing PBSC and t
o define its toxicity. Fifty-five MM patients received DCEP followed by GCS
F as part of high-dose programs including autologous transplantation. At th
e time of mobilization, 40 patients had previously received VAD only, and 1
5 alkylating agents. Mobilization was successful (minimum number of CD34(+)
cells 2 x 10(6)/kg) in 48/55 patients (87%), and 41/55 patients (75%) coll
ected >4 x 10(6)/kg CD34(+) cells. Of the seven patients who did not mobili
ze stem cells, five (71%) had been previously exposed to alkylating agents.
The median number of CD34(+) cells harvested was 5.8 x 10(6)/kg (range 2.1
-22.4). There was no treatment-related mortality. The side-effects of DCEP
were always tolerable. No neutropenia < 1000/mul nor thrombocytopenia < 500
00/mul were observed. No patient required transfusion as a consequence of t
herapy, or hospitalization for septic complications. In conclusion, DCEP, i
n addition to its demonstrated anti-tumor activity, is an effective regimen
for mobilizing peripheral blood progenitor cells in myeloma patients, with
little or no side-effects. These properties render DCEP a useful regimen f
or the debulking and mobilization phase of high-dose programs for multiple
myeloma.